Search - tctmd.com

Displaying 141 - 160 of 261

Sort: Relevancy | Date

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

News Conference News ESC 2014

PROTECT: ZES Sustain Lead Over SES at 5 Years

Caitlin E. Cox

September 03, 2014

News Daily News

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

L.A. McKeown

September 02, 2014

Presentation ESC 2014

Randomised comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous coronary revascularization

Presenter: Thomas Pilgrim

September 01, 2014

News Conference News ESC 2014

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Yael L. Maxwell

September 01, 2014

News Daily News

Similar Overall Long-Term Outcomes, Less Stent Thrombosis with Newer DES in STEMI

Todd Neale

August 22, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Daily News

Stent Malapposition Frequent, But Without Clinical Consequences

Jason Kahn

January 27, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

Presentation TCT 2013

TCT-39. 12-Month Angiographic and Clinical Results of the ReZolve® Sirolimus-Eluting Bioresorbable Coronary Scaffold: The RESTORE trial

Presenter: Ricardo Costa

October 29, 2013

Presentation TCT 2013

TCT-29. First-in-Man Study of Dedicated Bifurcation Sirolimus-Eluting Stent BiOSS LIM

Presenter: Robert Gil

October 29, 2013

Presentation TCT 2013

TCT-20. Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Corona...

Presenter: Yelin Zhao

October 29, 2013

Presentation TCT 2013

TCT-12. Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents

Presenter: Michael Maeng

October 29, 2013

Presentation TCT 2013

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Presenter: Laura Mauri

October 28, 2013

Presentation TCT 2013

Update on the DREAMS Paclitaxel-eluting and Sirolimus-eluting Magnesium Scaffolds: Device Design, Elution Kinetics, Imaging and Extended Clinical Results

Presenter: Michael Haude

October 27, 2013

Presentation TCT 2013

ReZolve Sirolimus-eluting BRS Based on an Iodinated Tyrosine Derivative: Device Iteration and Extended Imaging and Clinical Results

Presenter: Ricardo Costa

October 27, 2013

Presentation TCT 2013

MiStent: 2-year Randomized Trial Results from a Sirolimus-eluting Stent with a Bioabsorbable Coating

Presenter: John Ormiston

October 27, 2013

Presentation TCT 2013

FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-eluting Stent: Update on the FIH, TARGET I, and TARGET II Trials

Presenter: Bo Xu

October 27, 2013

Advertisement

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

PROTECT: ZES Sustain Lead Over SES at 5 Years

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

Randomised comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous coronary revascularization

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Similar Overall Long-Term Outcomes, Less Stent Thrombosis with Newer DES in STEMI

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

Stent Malapposition Frequent, But Without Clinical Consequences

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

TCT-39. 12-Month Angiographic and Clinical Results of the ReZolve® Sirolimus-Eluting Bioresorbable Coronary Scaffold: The RESTORE trial

TCT-29. First-in-Man Study of Dedicated Bifurcation Sirolimus-Eluting Stent BiOSS LIM

TCT-20. Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Corona...

TCT-12. Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents

PROTECT: Four-Year Results from a Prospective, Randomized Trial of Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents

Update on the DREAMS Paclitaxel-eluting and Sirolimus-eluting Magnesium Scaffolds: Device Design, Elution Kinetics, Imaging and Extended Clinical Results

ReZolve Sirolimus-eluting BRS Based on an Iodinated Tyrosine Derivative: Device Iteration and Extended Imaging and Clinical Results

MiStent: 2-year Randomized Trial Results from a Sirolimus-eluting Stent with a Bioabsorbable Coating

FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-eluting Stent: Update on the FIH, TARGET I, and TARGET II Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content